Human Articular Cartilage and Chondrocytes Produce Hemopoietic Colony-stimulating Factors in Culture in Response to IL-1
Overview
Authors
Affiliations
The hemopoietic CSF, granulocyte-macrophage CSF (GM-CSF) and granulocyte CSF (G-CSF), are cytokines that mediate the clonal proliferation and differentiation of progenitor cells into mature macrophages and/or granulocytes. We have employed an all-human cell culture system, specific ELISA for GM-CSF and G-CSF, and Northern analysis to investigate whether chondrocytes are a potential source of CSF in rheumatoid disease. We report that human rIL-1 stimulated in a dose-dependent manner the production of GM-CSF and G-CSF by human articular cartilage and chondrocyte monolayers in organ and cell culture, respectively. Increased levels of the CSF Ag were detected after 2 to 8 h stimulation with IL-1, and the optimum dose of IL-1 was 10 to 100 U/ml (0.06 to 0.6 nM IL-1 alpha; 0.02 to 0.2 nM IL-1 beta); neither CSF was detectable in nonstimulated cultures nor in IL-1-stimulated cultures treated with actinomycin D or cycloheximide, indicating the requirement for de novo RNA and protein synthesis. The IL-1-mediated increase in GM-CSF could also be inhibited by the corticosteroid, dexamethasone, but not by the cyclo-oxygenase inhibitor, indomethacin. Although having little effect when tested alone, TNF-alpha and lymphotoxin (TNF-beta) could synergize with IL-1 for the production of GM-CSF. Basic fibroblast growth factor, platelet-derived growth factor, and IFN-alpha and IFN-gamma each had no effect on GM-CSF levels. Results obtained by Northern analysis of chondrocyte total RNA reflected those found for the CSF Ag, namely that CSF mRNA levels were elevated in response to IL-1, but not TNF, and that there was synergy between these two cytokines. We propose that chondrocyte CSF production in response to IL-1, and the concurrent destruction of cartilage by IL-1, could provide a mechanism for the chronic nature of rheumatoid disease.
Mechanism of Emodin in the Treatment of Rheumatoid Arthritis.
Cheng L, Chen J, Rong X Evid Based Complement Alternat Med. 2022; 2022:9482570.
PMID: 36225183 PMC: 9550445. DOI: 10.1155/2022/9482570.
A low dose cell therapy system for treating osteoarthritis: study and mechanistic investigations.
Wang B, Liu W, Li J, Chai S, Xing D, Yu H Bioact Mater. 2021; 7:478-490.
PMID: 34466747 PMC: 8379370. DOI: 10.1016/j.bioactmat.2021.05.029.
Lauer J, Selig M, Hart M, Kurz B, Rolauffs B Int J Mol Sci. 2021; 22(6).
PMID: 33807043 PMC: 8004672. DOI: 10.3390/ijms22063279.
Crotti C, Agape E, Becciolini A, Biggioggero M, Favalli E Drugs. 2019; 79(16):1741-1755.
PMID: 31486005 DOI: 10.1007/s40265-019-01192-z.
Roles of GM-CSF in the Pathogenesis of Autoimmune Diseases: An Update.
Lotfi N, Thome R, Rezaei N, Zhang G, Rezaei A, Rostami A Front Immunol. 2019; 10:1265.
PMID: 31275302 PMC: 6593264. DOI: 10.3389/fimmu.2019.01265.